Los Angeles Capital Management
MDGL icon

Los Angeles Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Los Angeles Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Buy
3,920
+2,878
+276% +$1.47M 0.01% 583
2026
Q1 		$545K Sell
1,042
-4,561
-81% -$2.18M ﹤0.01% 848
2025
Q4 		$2.4M Buy
5,603
+479
+9% +$245K 0.01% 412
2025
Q3 		$2.35M Sell
5,124
-25
-0.5% -$9.33K 0.01% 462
2025
Q2 		$1.56M Buy
5,149
+2,553
+98% +$761K 0.01% 505
2025
Q1 		$860K Sell
2,596
-156
-6% -$51.3K ﹤0.01% 604
2024
Q4 		$849K Buy
+2,752
New +$774K ﹤0.01% 670
2023
Q2 		– Sell
-1,029
Closed -$249K – 1234
2023
Q1 		$249K Buy
+1,029
New +$280K ﹤0.01% 1072
2021
Q2 		– Sell
-6,260
Closed -$732K – 1619
2021
Q1 		$732K Sell
6,260
-5,202
-45% -$607K ﹤0.01% 1049
2020
Q4 		$1.27M Buy
11,462
+125
+1% +$15.3K 0.01% 828
2020
Q3 		$1.35M Sell
11,337
-1,660
-13% -$180K 0.01% 702
2020
Q2 		$1.47M Buy
12,997
+255
+2% +$25.1K 0.01% 711
2020
Q1 		$851K Buy
+12,742
New +$1.06M 0.01% 754
2019
Q3 		– Sell
-2,053
Closed -$215K – 1323
2019
Q2 		$215K Buy
+2,053
New +$220K ﹤0.01% 1279

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Los Angeles Capital Management's MDGL Position: Q2 2026 in Review

Los Angeles Capital Management increased its Madrigal Pharmaceuticals (MDGL) stake by 276% in Q2 2026, buying an estimated $1.47M and bringing the position to 3,920 shares worth $2.1M. The position accounts for 0.01% of the portfolio, ranked #583.

Los Angeles Capital Management first reported a position in MDGL in Q2 2019 and has held it in 14 quarters since. The position peaked at $2.4M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Los Angeles Capital Management held 3,920 shares of Madrigal Pharmaceuticals worth $2.1M as of Q2 2026.
  • Los Angeles Capital Management bought 2,878 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $1.47M.
  • Madrigal Pharmaceuticals made up 0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #583 holding.
  • Los Angeles Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2019 and has held it in 14 quarters since.
  • Los Angeles Capital Management's Madrigal Pharmaceuticals position peaked at $2.4M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.